Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short-term Investments (2020 - 2025)

Apellis Pharmaceuticals has reported Short-term Investments over the past 6 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Short-term Investments at $1.5 million for Q4 2025, up 15.51% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 15.51% YoY), and the annual figure for FY2025 was $1.5 million, up 15.51%.
  • Short-term Investments for Q4 2025 was $1.5 million at Apellis Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over the last five years, Short-term Investments for APLS hit a ceiling of $458.2 million in Q1 2021 and a floor of $1.1 million in Q2 2023.
  • Median Short-term Investments over the past 5 years was $1.4 million (2024), compared with a mean of $27.1 million.
  • Peak annual rise in Short-term Investments hit 4667.61% in 2021, while the deepest fall reached 99.7% in 2021.
  • Apellis Pharmaceuticals' Short-term Investments stood at $60.4 million in 2021, then crashed by 97.89% to $1.3 million in 2022, then decreased by 12.49% to $1.1 million in 2023, then increased by 18.67% to $1.3 million in 2024, then grew by 15.51% to $1.5 million in 2025.
  • The last three reported values for Short-term Investments were $1.5 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.